Establishing mesothelioma patient-derived organoid models from malignant pleural effusions

Lung Cancer 2024 March 28 [Link]

Ashleigh J Hocking, Lauren A Mortimer, Alexandra L Farrall, Prudence A Russell, Sonja Klebe

Abstract

Objectives: Pleural mesothelioma is a cancer arising in the cells that line the lungs and chest wall with poor survival and poor response to first-line therapy. Organoid models of cancer can faithfully recapitulate the genetic and histopathological characteristics of individualized tumors and have potential to be used for precision medicine, however methods of establishing patient-derived mesothelioma organoids have not been well established in the published literature.

Materials and methods: Long-term mesothelioma patient-derived organoids were established from ten malignant pleural effusion fluids. Mesothelioma patient-derived organoids were compared to the corresponding biopsy tissue specimens using immunohistochemistry labelling for select diagnostic markers and the TruSight Oncology-500 sequencing assay. Cell viability in response to the chemotherapeutic drug cisplatin was assessed.

Results: We established five mesothelioma patient-derived organoid cultures from ten malignant pleural effusion fluids collected from nine individuals with pleural mesothelioma. Mesothelioma patient-derived organoids typically reflected the histopathological and genomic features of patients’ matched biopsy specimens and displayed cytotoxic sensitivity to cisplatin in vitro.

Conclusion: This is the first study of its kind to establish long-term mesothelioma organoid cultures from malignant pleural effusions and report on their utility to test individuals’ chemotherapeutic sensitivities ex vivo.